Biotheus pipeline
WebClinical pipeline. TILT’s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human T- cell stimulating cytokines; TNF alpha and IL-2. ... In 2024, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of ... WebDec 3, 2024 · Biotheus Inc. is a biotechnology company based in Zhuhai, Guangdong, China with multiple clinical-stage assets under clinical development. Biotheus' management team has broad experience from drug discovery to NDA filing in the US and China and is developing a broad me-better/novel target pipeline focused on immuno-oncology and …
Biotheus pipeline
Did you know?
WebIn our pipeline, our lead therapeutic asset, TILT-123, is a cytokine armed oncolytic adenovirus that is currently in Phase 1 clinical trials as monotherapy and in combination with tumor infiltrating lymphocytes (TIL) therapy in Europe. ... MSD International GmbH, and Biotheus, a privately held Chinese biotechnology company. WebMar 4, 2024 · Biotheus Inc. raised $100 million at the close of its fourth round of financing led by General Atlantic Service Co. LP and IDG Ventures. New investors Kunlun Group Ltd., CITIC Private Equity Funds Management Co. Ltd., Shenzhen Co-win Venture Capital Investments Ltd. as well as existing investors HighLight Capital, Shenzhen Shiyu …
WebMar 3, 2024 · This is supported by the company's product pipeline, which consists of over 10 novel monoclonal and multispecific antibodies. Biotheus currently has two bispecific antibodies in phase I clinical development for cancer treatment, and a third IND application was submitted at the end of 2024. ... "Biotheus has built multiple platforms critical for ... WebDetails. Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class …
WebBiotheus is a pharmaceutical company that aims to discover and develop effective therapeutic biologics for patients with cancer and metabolic diseases. Use the CB … WebJan 19, 2024 · Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that 12 new partner programs entered clinical development in 2024, including programs by Biotheus, Dragonfly, IASO, Iconic, Innovent, Mapp Biopharmaceutical, and Surface Oncology. This brings the …
WebJun 1, 2024 · Alligator's pipeline includes five lead clinical and preclinical drug candidates: mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical ...
WebProduct Pipeline-Biotheus-In the future, Biotheus will quickly become the first echelon of domestic biopharmaceutical companies with its high-value product chain, strong … inclusion\u0027s iyWebNov 15, 2024 · With a well-seasoned development team, Biotheus has built up a robust pipeline inclusive of 10 programs at different stages of clinical development. For more information about Biotheus, please ... incarnation oviedo flWebBiotheus is a pharmaceutical company that aims to discover and develop effective therapeutic biologics for patients with cancer and metabolic diseases. Use the CB Insights Platform to explore Biotheus's full profile. ... Adimab Provides 2024 Update on Clinical Pipeline. Dec 7, 2024. Gene Amplification Technologies market is projected to grow at ... incarnation parish chicagoWebNational Center for Biotechnology Information inclusion\u0027s izWebJan 27, 2024 · Biotheus’ management team has broad experience from drug discovery to NDA filing in China and is developing a broad me-better/novel target pipeline focused on … inclusion\u0027s jhWebDec 3, 2024 · ZHUHAI, China, Dec. 3, 2024 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been … incarnation parish charlottesvilleWebAlligators Bioscience’s portfolio comprise the drug candidates mitazalimab, ATOR-1017 and ALG.APV-527, as well as the drug concept Neo-X-Prime™, all of which are intended for the treatment of metastatic cancers. The … inclusion\u0027s jt